Cargando…

Can We Predict Skeletal Lesion on Bone Scan Based on Quantitative PSMA PET/CT Features?

SIMPLE SUMMARY: Treating patients for metastatic prostate cancer based on the information of PSMA-PET bears the risk to “under- or overtreat” patients, given that many lesions seen only on PSMA-PET but not on conventional imaging (CI) could alter their management. It is not possible to predict the d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laudicella, Riccardo, Bauckneht, Matteo, Maurer, Alexander, Heimer, Jakob, Gennari, Antonio G., Di Raimondo, Tania, Paone, Gaetano, Cuzzocrea, Marco, Messerli, Michael, Eberli, Daniel, Burger, Irene A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670186/ https://www.ncbi.nlm.nih.gov/pubmed/38001731 http://dx.doi.org/10.3390/cancers15225471

Ejemplares similares

Frequency and intensity of [(18)F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET
por: Maurer, Alexander, et al.
Publicado: (2022)

What’s behind (68)Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns
por: Rüschoff, Jan H., et al.
Publicado: (2021)

Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI
por: Laudicella, Riccardo, et al.
Publicado: (2022)

Hot needles can confirm accurate lesion sampling intraoperatively using [(18)F]PSMA-1007 PET/CT-guided biopsy in patients with suspected prostate cancer
por: Ferraro, Daniela A., et al.
Publicado: (2021)

Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with (68)Ga-PSMA-11-PET
por: Ferraro, Daniela A., et al.
Publicado: (2020)

Improved oncological outcome after radical prostatectomy in patients staged with (68)Ga-PSMA-11 PET: a single-center retrospective cohort comparison
por: Ferraro, Daniela A., et al.
Publicado: (2020)

Surveys on COVID-19 in nuclear medicine: what happened and what we learned
por: Annunziata, Salvatore, et al.
Publicado: (2020)

(68)Ga-PSMA-11 PET/MRI versus multiparametric MRI in men referred for prostate biopsy: primary tumour localization and interreader agreement
por: Ferraro, Daniela A., et al.
Publicado: (2022)

PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature
por: Alongi, Pierpaolo, et al.
Publicado: (2022)

Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review
por: Triumbari, Elizabeth Katherine Anna, et al.
Publicado: (2022)

Combined forced diuresis and late acquisition on [(68)Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study
por: Bauckneht, Matteo, et al.
Publicado: (2023)

Prostate Cancer Biochemical Recurrence Resulted Negative on [(68)Ga]Ga-PSMA-11 but Positive on [(18)F]Fluoromethylcholine PET/CT
por: Laudicella, Riccardo, et al.
Publicado: (2022)

Diagnostic performance of (68)Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study
por: Ferraro, Daniela A., et al.
Publicado: (2021)

(68)Ga-PSMA-11 PET imaging in patients with ongoing androgen deprivation therapy for advanced prostate cancer
por: Fassbind, Saskia, et al.
Publicado: (2021)

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
por: Rauscher, Isabel, et al.
Publicado: (2016)

PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet?
por: Maurer, Tobias, et al.
Publicado: (2017)

Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer
por: Kallur, Kumaraswamy G, et al.
Publicado: (2017)

Cardiac Metastasis from Prostate Cancer: A Case Study Underlying the Crucial Role of the PSMA PET/CT
por: Gandini, Annalice, et al.
Publicado: (2023)

Commentary: When we don't know what we don't know
por: Paone, Gaetano
Publicado: (2020)

Radiomics analysis improves (18)FDG PET/CT-based risk stratification of cytologically indeterminate thyroid nodules
por: Giovanella, Luca, et al.
Publicado: (2021)

Super Early Scan of PSMA PET/CT in Evaluating Primary and Metastatic Lesions of Prostate Cancer
por: Mao, Juanli, et al.
Publicado: (2022)

Improved Prostate-Specific Membrane Antigen (PSMA) Stimulation Using a Super Additive Effect of Dutasteride and Lovastatin In Vitro
por: Kuzmanov, Aleksandar, et al.
Publicado: (2023)

The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer
por: Erdoğan, Mehmet, et al.
Publicado: (2020)

Limited benefit of additional contrast-enhanced CT to end-of-treatment PET/CT evaluation in patients with follicular lymphoma
por: Paone, Gaetano, et al.
Publicado: (2021)

PSMA PET in Imaging Prostate Cancer
por: Tsechelidis, Ioannis, et al.
Publicado: (2022)

The value of (68)Ga-PSMA enhanced PET-CT and MR-PET in patients with biochemical recurrent prostate cancer
por: Rummeny, E, et al.
Publicado: (2015)

Two Birds with One Stone: Hepatocellular Carcinoma and Small Cell Lung Cancer Imaged with [(18)F]Fluorocholine Positron Emission Tomography/Computed Tomography
por: Cuzzocrea, Marco, et al.
Publicado: (2023)

Evaluation of [(68) Ga]Ga-PSMA-I&T PET/CT with additional late scans of the pelvis in prostate-specific antigen recurrence using the PROMISE criteria
por: Koehler, Daniel, et al.
Publicado: (2022)

All that Glitters on PSMA is Not a Lesion: An Unusual Artifact on PSMA PET/CT
por: Dev, Indraja D., et al.
Publicado: (2021)

68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now?
por: Witkowska-Patena, Ewa, et al.
Publicado: (2017)

[(18)F]FDG uptake of axillary lymph nodes after COVID-19 vaccination in oncological PET/CT: frequency, intensity, and potential clinical impact
por: Skawran, Stephan, et al.
Publicado: (2021)

Quantitative imaging parameters to predict the local staging of prostate cancer in intermediate- to high-risk patients
por: Laudicella, Riccardo, et al.
Publicado: (2022)

PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature
por: Muselaers, Stijn, et al.
Publicado: (2022)

PSMA PET-directed surgical metastasis-directed therapy in metachronous prostate cancer
por: Ambrosini, Francesca, et al.
Publicado: (2023)

Can PSMA PET/CT help in dose-tailoring in post-prostatectomy radiotherapy?
por: Champion, Ambroise, et al.
Publicado: (2023)

Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?
por: Demirci, Emre, et al.
Publicado: (2019)

The meta-analysis of the effect of (68)Ga-PSMA-PET/CT diagnosis of prostatic cancer compared with bone scan
por: Zhao, Ruining, et al.
Publicado: (2021)

Evaluating a Machine Learning Tool for the Classification of Pathological Uptake in Whole-Body PSMA-PET-CT Scans
por: Erle, Annette, et al.
Publicado: (2021)

PSMA Expression in Multinodular Thyroid Neoplasm on Simultaneous Ga-68-PSMA PET/MRI
por: Jena, Amarnath, et al.
Publicado: (2017)

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
por: Ceci, Francesco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0ecl50evgnvadd9c3qdba47jpb